Business Wire

Shisha Is the Most Valuable Player for Thousands of Bars and Cafés – New Research Shows

25.10.2024 19:06:00 CEST | Business Wire | Press release

Share

AIR Group Limited, the world’s largest producer of shisha molasses, owner of the famous Al Fakher brand and the inventor of the OOKA, the world’s first charcoal free pod-based shisha system, has released new research on the role of shisha in microbusinesses such as bars and cafés in the Middle East, Europe and the United States.

The study involved hundreds of interviews with bar, restaurant and café owners and managers in the UAE, Saudi Arabia, Germany, Spain and the US.

On average, circa 8 in 10 of the businesses surveyed identified shisha as the highest margin product item in their venues.

According to Ronan Barry, Chief Corporate Affairs Officer of AIR Group, “This shows us that shisha is among the most equitable fast moving consumer goods (aka FMCG’s) in the world. In most FMCG and lifestyle product categories the majority of the value accrues to the brand owner with some scraps left over for the broader value chain. But in shisha, the value is more equitably distributed with the lion’s share going to the smallest businesses in the chain, those who serve the experience to the consumer.”

“We have long suspected that shisha is likely the Most Valuable Player (MVP) in the hospitality sector. These businesses enjoy margins on shisha of up to 95%, compared to about 5% on average in food.”

There are over a hundred thousand hospitality venues serving shisha and according to the sample surveyed by AIR, if these businesses did not serve shisha, their very survival would be in doubt. Almost half of survey respondents would close their doors if they were unable to offer shisha.

According to Garth Beer, who manages a shisha catering business providing shisha service to dozens of bars, restaurants and night clubs, “Shisha plays a critical role in drawing customers into the venue and in keeping them there. In some cases, its ‘come for the shisha, stay for the food and drink’ while in others its ‘come for the food, stay for a shisha’ and that the after-dinner shisha can be the difference between a profitable table and a non-profitable table.”

However, the boom of shisha remains unavailable to a majority of bars and restaurants due to the use of charcoal to heat the molasses and generate the cloud for the customers to enjoy. Charcoal is both a fire hazard and a source of toxic chemicals in indoor environments, requiring significant investments in fire safety and ventilation. AIR’s newest innovation, a revolutionary charcoal free, pod-based shisha system offers the opportunity for more microbusinesses to reap the benefits of shisha services because it removes charcoal and side streams smoke entirely, leaving a much cleaner shisha cloud for the consumer to enjoy. Already OOKA has been embraced by almost 250 bars and restaurants in Germany and in the UAE.

According to Mario, General Manager of a premium night club in Dubai “We, regrettably, had to exclude shisha from our club due to the smoke and fire safety concerns even though guests have been asking for it.

“We’ve had OOKA for a few months now and the feedback from our customers is fantastic. We’re on track to have a record season and it’s clear that OOKA will be a major contributor to that.”

AIR will continue to work with hospitality businesses around the world to support them in adopting shisha and OOKA and also in supporting the training of their staff to ensure that they can confidently offer the best customer experience in every serving.

About AIR (ADVANCED INHALATION RITUALS)

AIR is the market leader in the $19 billion global shisha market, with an aim to provide superior physical, emotional and mental benefits through inhalation. Launched in 1999 and headquartered in Dubai, the business has a multinational presence in over 100 countries across the UAE, Europe, North America, India, and Africa.

AIR holds 47% of the shisha category market share in the markets it is present it and is the leading business in a market set to grow to $22 billion in 2026. Its portfolio of companies includes Al Fakher, the world’s leading shisha brand; Hookah-Shisha.com, the world’s number one e-commerce platform for hookahs and shisha; Shisha Kartel, a Dubai-based shisha manufacturer; and Shisha.com, a global online community of shisha and hookah users. Advanced Inhalation Rituals’ science program, conducted in partnership with independent accredited laboratories, enables the development innovative products that combine centuries of tradition with cutting edge innovation to minimise harm and maximise enjoyment for millions around the world. The business has consistently outperformed competitors growing at 3x the market rate over the last 10 years, due to heavy investment in innovation, product, and user experience.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241025730501/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye